Gritstone Bio EBIT 2017-2024 | GRTSQ
Gritstone Bio ebit from 2017 to 2024. Ebit can be defined as earnings before interest and taxes.
Gritstone Bio Annual EBIT (Millions of US $) |
2023 |
$-140 |
2022 |
$-120 |
2021 |
$-75 |
2020 |
$-106 |
2019 |
$-98 |
2018 |
$-66 |
2017 |
$-42 |
2016 |
$-19 |
Gritstone Bio Quarterly EBIT (Millions of US $) |
2024-06-30 |
$-28 |
2024-03-31 |
$-40 |
2023-12-31 |
$-30 |
2023-09-30 |
$-39 |
2023-06-30 |
$-36 |
2023-03-31 |
$-35 |
2022-12-31 |
$-32 |
2022-09-30 |
$-30 |
2022-06-30 |
$-30 |
2022-03-31 |
$-29 |
2021-12-31 |
$-30 |
2021-09-30 |
$-28 |
2021-06-30 |
$-25 |
2021-03-31 |
$8 |
2020-12-31 |
$-27 |
2020-09-30 |
$-26 |
2020-06-30 |
$-26 |
2020-03-31 |
$-27 |
2019-12-31 |
$-28 |
2019-09-30 |
$-28 |
2019-06-30 |
$-22 |
2019-03-31 |
$-19 |
2018-12-31 |
$-18 |
2018-09-30 |
$-19 |
2018-06-30 |
$-16 |
2018-03-31 |
$-13 |
2017-12-31 |
|
2017-09-30 |
$-9 |
2016-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|